Welcome to our dedicated page for Ikena Oncology SEC filings (Ticker: IKNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings associated with the historical ticker IKNA document the regulatory and corporate path of Ikena Oncology, Inc. as it transitioned into neBio, Inc. and shifted its Nasdaq listing to the ticker IMA. These filings include multiple Forms 8-K that describe material events such as the execution and completion of the merger with Inmagene Biopharmaceuticals, the 1-for-12 reverse stock split of Ikena common stock, and the formal change of the corporate name from Ikena Oncology, Inc. to neBio, Inc.
Within these documents, investors can find detailed descriptions of the Agreement and Plan of Merger, the two-step merger structure that made Inmagene a wholly owned subsidiary, and the resulting ownership structure of the combined company. Other filings outline the approval and implementation of new equity incentive and employee stock purchase plans that become effective after the merger, as well as the creation of contingent value rights agreements for Ikena’s legacy assets, including IK-595, and certain Inmagene assets other than -007.
Additional 8-K filings cover corporate actions such as the adoption of a 2025 Inducement Plan, the dismissal of Ernst & Young LLP as the independent registered public accounting firm and the engagement of PricewaterhouseCoopers LLP, and the mechanics and timing of the reverse stock split and new listing details on The Nasdaq Capital Market under IMA. Earlier filings and periodic reports referenced in these documents provide context on Ikena’s targeted oncology programs, including IK-930 and IK-595, and its completed collaboration with Bristol-Myers Squibb.
On Stock Titan’s filings page, users can access these SEC documents in one place and use AI-powered tools to surface key elements such as merger terms, reverse split ratios, contingent value rights mechanics, and changes in auditors or compensation plans. This helps readers quickly understand how Ikena’s historical IKNA listing evolved into neBio, Inc.’s current IMA listing and how legacy oncology and inflammatory disease assets are treated in the company’s regulatory record.
Form 4 – ImageneBio, Inc. (ticker IKNA)
Chief Financial Officer Jotin Marango disclosed merger-related equity adjustments tied to the 25 Jul 2025 closing of ImageneBio’s combination with Inmagene Biopharmaceuticals (formerly Ikena Oncology). On 28 Jul 2025 the CFO received 15,776 common shares (code A) issued in exchange for former Ikena options. To cover withholding taxes, 4,630 shares were automatically surrendered at $17.16 per share (code F), leaving a direct holding of 11,146 shares.
All legacy Ikena stock options were cancelled (code D): 181,000; 105,000; and 397,199 options, totalling 683,199 contracts. Following the transactions Marango holds no derivative securities.
The filing reflects mandatory conversion mechanics of the merger rather than discretionary trading, so its informational value is limited. Nonetheless, the CFO now has an equity stake in the combined company, aligning interests with shareholders.
Amendment No. 1 to Schedule 13D shows that BML Investment Partners, L.P. and its managing member, Braden M. Leonard, have materially reduced their position in Ikena Oncology (IKNA).
- Open-market sales between 16-22 Jul 2025 totalled 1,459,110 shares at $1.20-$1.30 per share.
- Current ownership: BML Investment Partners 215,832 shares; Leonard 5,000 shares; aggregate 220,832 shares.
- The cover page lists the stake as 1.9 % of outstanding shares; Item 5 cites 8.35 %, signalling an internal discrepancy.
The filing states the shares were acquired for investment purposes, the group is now below the 5 % reporting threshold, and it has no present plans to influence corporate actions. Future trades may occur depending on market conditions. No contracts or arrangements with other parties were disclosed.
ImageneBio, Inc. (formerly Ikena Oncology, Inc.) has filed an 8-K to confirm that on 25 Jul 2025 it closed the previously announced merger with Cayman-based Inmagene Biopharmaceuticals. Two wholly owned Cayman merger subsidiaries were used to combine Inmagene into the Delaware parent, leaving Inmagene as a wholly owned subsidiary.
Immediately after closing, the registrant changed its corporate name to “ImageneBio, Inc.” and updated its Nasdaq listing to the new ticker IMA. The company furnished, under Item 7.01 (Reg FD), a press release (Exhibit 99.1) announcing completion of the transaction; the release is incorporated by reference but not deemed “filed.” No consideration details, pro-forma financials or other quantitative information are provided in this report.